“…In comparison, both ER/PR were positive in more than 75% of patients and HER2 is lower than 40% in patients without MPD. Based on Arsenal et al data, MPD-IDC patients showed expression of ER and PR in 38.5% and 33.3%, respectively, and HER2 overexpression in 41% (23). In another study, overexpression of the HER2/neu (c-erb-B2) oncogene was detectable in 83% of cases (11).…”